Accendra Health Sees Only 40% EBITDA in H1 2026, Faces $300M Payer Loss
Accendra Health projects only 40% of adjusted EBITDA in H1 2026 after cost-reduction ramp and a $300 million revenue loss from a large payer. It generated $135 million in Q4 2025 operating cash flow, paid down $65 million of debt, divested its former business and launched the MyApria app.
1. Q1 2026 Guidance and EBITDA Impact
Accendra Health forecasts only 40% of its full-year adjusted EBITDA in the first half of 2026, driven by ramping cost-reduction initiatives and the anticipated $300 million revenue shortfall from the loss of a major commercial payer. This guidance underscores the company’s transition and the need to realign pricing and operations to weather margin pressures in home-based care.
2. 2025 Q4 Cash Flow and Debt Reduction
In the fourth quarter of 2025, the company generated $135 million in cash from operating activities and applied $65 million of ordinary free cash flow to debt reduction. This strong cash-generation profile supports its commitment to strengthening the balance sheet and optimizing capital structure going into 2026.
3. Divestiture and Strategic Focus
Accendra completed the divestiture of its former products and healthcare services business, eliminating stranded costs and sharpening focus on high-margin core home-based care operations. Proceeds from the sale will be redeployed toward targeted investments and margin enhancement in its primary brands, Byram and Apria.
4. Technology Initiatives and Market Position
The launch of the MyApria app marks a push toward automation and improved customer experience to counter rising manufacturer costs and inflation. Backed by Net Promoter Scores above industry averages and payer relationships reaching 300 million Americans, the company aims to reinforce its leadership in chronic care delivery.